Type of security: Stock
Sector: Health Care
The data is delayed by 15 minutes.
Description: Vermillion, Inc., together with its subsidiaries, is engaged in the discovery, development, and commercialization of diagnostic tests that help physicians diagnose, treat, and enhance outcomes for patients. It develops diagnostic tests in the fields of oncology and women?s health. The company?s lead product is OVA1, an ovarian cancer blood test for pre-surgical identification of women who are at high risk of having a malignant ovarian tumor. It serves clinical reference laboratories, hospital laboratories, and physician offices. The company was founded in 1993 and is headquartered in Austin, Texas.
|Shares Outstanding||EPS||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||193.52%||Sales Growth - Q/Q||-39.39%||P/E|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-103.66%||ROE||-127.45%||ROI|
|Current Ratio||5.19||Quick Ratio||Long Term Debt/Equity||Debt Ratio||0.23|
|Gross Margin||47.4%||Operating Margin||-615.03%||Net Profit Margin||-611.27%||Dividend Payout Ratio|
|Cash From Financing Activities||-1.16 M||Cash From Investing Activities||-40 K||Cash From Operating Activities||-4.53 M||Gross Profit||460 K|
|Net Profit||-4.14 M||Operating Profit||-4.26 M||Total Assets||18.68 M||Total Current Assets||18.09 M|
|Total Current Liabilities||3.48 M||Total Debt||Total Liabilities||3.48 M||Total Revenue||950 K|
|High 52 week||1.58||Low 52 week||0.29||Last close||0.71||Last change||-5.62%|
|RSI||39.63||Average true range||0.08||Beta||0.59||Volume||32.31 K|
|Simple moving average 20 days||-5.07%||Simple moving average 50 days||17.65%||Simple moving average 200 days||4.52%|
|Performance Week||-11.88%||Performance Month||-3.42%||Performance Quart||42.48%||Performance Half||21.55%|
|Performance Year||-48.16%||Performance Year-to-date||135%||Volatility daily||4.9%||Volatility weekly||10.96%|
|Volatility monthly||22.46%||Volatility yearly||77.82%||Relative Volume||196.24%||Average Volume||144.55 K|
|New High||New Low|
2019-01-22 12:46:47 | Could Vermillion, Inc.’s NASDAQ:VRML Investor Composition Influence The Stock Price?
2019-01-15 09:46:46 | Vermillion Announces Coverage by Cigna for OVA1® MIA
2018-12-14 13:24:01 | What Investors Should Know About Vermillion, Inc.’s NASDAQ:VRML Financial Strength
2018-11-20 16:01:00 | Vermillion to Present at the Piper Jaffray 30th Annual Healthcare Conference
2018-11-14 08:00:00 | New Research Coverage Highlights Nexa Resources S.A, Qumu, Clearway Energy, Vermillion, Cantel Medical, and Theravance Biopharma — Consolidated Revenues, Company Growth, and Expectations for 2018
2018-11-12 08:00:00 | Vermillion to Present at the Canaccord Medical Technology & Diagnostics Forum
2018-11-09 12:16:36 | Is Vermillion Inc’s NASDAQ:VRML CEO Salary Justified?
2018-11-09 09:27:52 | Edited Transcript of VRML earnings conference call or presentation 8-Nov-18 9:30pm GMT
2018-11-08 17:12:48 | Vermillion: 3Q Earnings Snapshot
2018-11-08 16:01:00 | Vermillion Reports Third Quarter 2018 Financial Results
2018-10-09 08:00:00 | Vermillion, Inc. Announces the Launch of OVA1®+
2018-08-26 19:45:45 | Edited Transcript of VRML earnings conference call or presentation 9-Aug-18 8:30pm GMT
2018-08-21 16:01:00 | Vermillion, Inc. Appoints Nancy Cocozza to its Board of Directors
2018-08-09 17:07:21 | Vermillion: 2Q Earnings Snapshot
2018-08-09 16:01:00 | Vermillion Reports Second Quarter 2018 Financial Results
2018-06-26 11:56:44 | Analysts Expect Breakeven For Vermillion Inc NASDAQ:VRML
2018-06-13 11:08:18 | Vermillion Names Chris Goulart to Senior Vice President of Commercial Operations
2018-06-04 20:58:21 | At $1, Is Vermillion Inc NASDAQ:VRML A Buy?
2018-05-14 21:41:53 | Edited Transcript of VRML earnings conference call or presentation 14-May-18 8:30pm GMT
2018-05-14 16:44:15 | Vermillion: 1Q Earnings Snapshot
2018-05-14 16:01:00 | Vermillion Reports First Quarter 2017 Financial Results
2018-05-14 12:45:00 | Vermillion, Inc. to Host Earnings Call
2018-05-03 16:01:00 | Vermillion to Report First Quarter 2018 Financial Results on Monday, May 14
2018-04-04 12:31:14 | Vermillion Inc NASDAQ:VRML: Immense Growth Potential?
2018-03-23 14:28:16 | Did Vermillion Inc’s NASDAQ:VRML Recent Earnings Growth Beat The Trend?
2018-03-14 13:16:24 | Edited Transcript of VRML earnings conference call or presentation 13-Mar-18 8:30pm GMT
2018-03-13 16:19:28 | Vermillion reports 4Q loss
2018-03-13 16:01:00 | Vermillion Reports Fourth Quarter and Fiscal Year 2017 Financial Results
2018-03-13 12:00:00 | Vermillion, Inc. to Host Earnings Call
2018-03-07 16:01:00 | Vermillion to Present at the 30th Annual ROTH Conference
2018-02-23 08:00:00 | Vermillion to Present at the 2018 BTIG Healthcare Conference
2018-02-19 18:11:15 | What Is Vermillion Inc’s NASDAQ:VRML Share Price Doing?
2018-02-05 08:45:00 | Vermillion Announces the Grant of Two Ovarian Cancer Diagnostic Patents
2018-01-18 08:45:00 | Vermillion Announces Agreement with BlueCross BlueShield of Illinois
2018-01-01 09:13:39 | Vermillion, Inc. :VRML-US: Earnings Analysis: Q3, 2017 By the Numbers : January 1, 2018
2017-12-26 19:05:09 | Are Vermillion Inc’s NASDAQ:VRML Interest Costs Too High?
2017-12-19 08:45:00 | Vermillion Appoints Bob Beechey to Newly Created CFO Post
2017-11-21 08:45:00 | Vermillion to Present at the 29th Annual Piper Jaffray Healthcare Conference
2017-11-20 08:56:00 | ASPiRA Labs Announces Release of Final CMS Reimbursement Rate for OVA1
2017-11-16 08:45:00 | Vermillion Announces Publication of Foundational Health Economics Study
2017-11-09 18:41:01 | Edited Transcript of VRML earnings conference call or presentation 8-Nov-17 9:30pm GMT